Cargando…
Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist
PURPOSE: To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). METHODS: In this double-blind, placebo-controlled phase 1 study,...
Autores principales: | Ogasawara, Akihito, Ogawa, Kei, Ide, Ryosuke, Ikenaga, Yuka, Fukunaga, Chie, Nakayama, Satoshi, Tsuda, Minoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229459/ https://www.ncbi.nlm.nih.gov/pubmed/37060458 http://dx.doi.org/10.1007/s00228-023-03476-6 |
Ejemplares similares
-
Absorption, metabolism, and excretion of [
(14)C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers
por: Tsuda, Minoru, et al.
Publicado: (2023) -
Melanogenic effect of dersimelagon (MT‐7117), a novel oral melanocortin 1 receptor agonist
por: Suzuki, T., et al.
Publicado: (2021) -
Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis
por: Kondo, Masahiro, et al.
Publicado: (2022) -
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
por: Collet, Tinh-Hai, et al.
Publicado: (2017) -
Pro-resolving and anti-arthritic properties of the MC(1) selective agonist PL8177
por: Garrido-Mesa, Jose, et al.
Publicado: (2022)